Wyeth Consumer Healthcare promotes pre-filled spoons of Robitussin Cough & Chest Congestion DM (dextromethorphan/guaifenesin) and Cough & Cold CF (dextromethorphan/guaifenesin/phenylephrine) for adult convenience. The two Robitussin To Go products are available nationwide at a suggested retail price of $8.69 for 10-count packs, a spokeswoman said in an e-mail. The products are indicated for consumers 12 years and older. Wyeth markets the products to consumers who "want a portable form for added convenience when they're on the go or away from home," the spokeswoman added. Robitussin To Go uses the RiteDose delivery system from The Ritedose Corp., which provides a similar device for McNeil Consumer Healthcare's pediatric allergy products Zyrtec Perfect Measure (cetirizine) and Benadryl Perfect Measure (diphenhydramine) (1"The Tan Sheet" Oct. 19, 2009)
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.
The Council of the EU has made several key amendments to the legislative reform package, which it will now negotiate with the European Parliament.
The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.
